The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 17, 2015

Filed:

May. 02, 2014
Applicants:

Idenix Pharmaceuticals, Inc., Cambridge, MA (US);

The Centre National DE LA Recherche Scientifique, Paris-Cedex, FR;

L'universite Montpellier Ii, Montpellier, FR;

Inventors:

Richard Storer, Folkestone, GB;

Gilles Gosselin, Montpellier, FR;

David Dukhan, Montpellier, FR;

Frederic Leroy, Jonquieres, FR;

Assignee:

Idenix Pharmaceuticals, LLC, Cambridge, MA (US);

Attorney:
Int. Cl.
CPC ...
C07H 19/23 (2006.01); C07D 487/04 (2006.01); C07D 405/04 (2006.01); C07D 409/04 (2006.01); A61K 31/7052 (2006.01); A61K 31/5025 (2006.01); A61K 31/53 (2006.01); A61P 31/14 (2006.01); A61K 31/706 (2006.01); A61K 31/00 (2006.01); C07H 19/044 (2006.01); C07H 19/052 (2006.01); C07H 19/056 (2006.01); A61K 45/06 (2006.01); C07H 19/04 (2006.01);
U.S. Cl.
CPC ...
A61K 31/706 (2013.01); A61K 31/00 (2013.01); A61K 45/06 (2013.01); C07H 19/04 (2013.01); C07H 19/044 (2013.01); C07H 19/052 (2013.01); C07H 19/056 (2013.01); C07H 19/23 (2013.01);
Abstract

This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine. The optionally substituted pentofuranonucleoside, or a salt or prodrug thereof, may be administered alone or in combination with one or more optionally substituted pentofuranonucleosides or other anti-viral agents.


Find Patent Forward Citations

Loading…